Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01464593 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
A Phase 2 study, sponsored by Imunon.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01464593 is a Phase 2 study that was terminated before completion, run by Imunon. The registered enrollment target is 2 participants.
The verdict
NCT01464593, a Phase 2 study, was terminated before completion, sponsored by Imunon.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of Thermodox, a thermally sensitive liposomal doxorubicin, in combination with thermal ablation in the treatment of hepatic colorectal liver metastases (CRLM).
Interventions
- DRUG ThermoDox
- DRUG Lyso-Thermosensitive Liposomal Doxorubicin
- OTHER 5% Dextrose Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01464593
The ClinicalTrials.gov registry entry for NCT01464593 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Imunon, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ThermoDox is the first listed.
NCT01464593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01464593 about?
NCT01464593 is a clinical study titled "Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)". The purpose of this study is to determine the safety and efficacy of Thermodox, a thermally sensitive liposomal doxorubicin, in combination with thermal ablation in the treatment of hepatic colorectal liver metastases (CRLM).
What is the current status of trial NCT01464593?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2011-09. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01464593?
The interventions under investigation include: ThermoDox (DRUG), Lyso-Thermosensitive Liposomal Doxorubicin (DRUG), 5% Dextrose Solution (OTHER).
Who is sponsoring clinical trial NCT01464593?
This trial is sponsored by Imunon, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.